Document is current
Any future updates will be listed below
-
Authors
Grinda, Thomas
Morganti, Stefania
Hsu, Liangge
Yoo, Tae-Kyung
Kusmick, Ross J.
Aizer, Ayal A.
Giordano, Antonio
Leone, Jose P.
Hughes, Melissa
Tolaney, Sara M.
Lin, Nancy U.
Sammons, Sarah L.
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 16 February 2025
First Online: 5 March 2025
Competing interests
: T.G. discloses Travel fees from AstraZeneca, Gilead, and Pfizer. Consulting/Advisor role for AstraZeneca and Cancerologie-pratique. Research funding: Amgen. S.M. reports support from AstraZeneca and Menarini/Stemline. A.A. declares research funding from Varian and NH TherAguix as well as consulting for Novartis and Seagen. AG reported personal fees from Pfizer. J.P.L. received research funding from Kazia Therapeutics, Lilly and AstraZeneca. Consulting from Minerva Biotechnologies. N.U.L. reports institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle. Genetics (now Pfizer), Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., and Eisai; royalties from UpToDate; and travel support from Olema Pharmaceuticals. S.M.T. reports consulting/ advisory role Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/ Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA; research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep; and travel support from Eli, Lilly, Sanofi, and Gilead. SS declares research funding to their institution from Astra Zeneca, Eli Lilly, Relay, SEAGEN and Sermonix; and consulting fees from Foundation Medicine, Astra Zeneca, Daichii Sankyo, Eli Lilly, Pfizer, Incyclix, Relay, Gilead, Sermonix and Novartis. HL, TKY, RK authors declare no conflicts of interest.
